SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:79aa491e-8aa0-4f69-b2d8-f9427ef30dfa"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:79aa491e-8aa0-4f69-b2d8-f9427ef30dfa" > The role of the pro...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007264naa a2200853 4500
001oai:lup.lub.lu.se:79aa491e-8aa0-4f69-b2d8-f9427ef30dfa
003SwePub
008200423s2015 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/79aa491e-8aa0-4f69-b2d8-f9427ef30dfa2 URI
0247 a https://doi.org/10.1016/j.urolonc.2015.01.0182 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Cremers, Ruben G.u Radboud University Medical Center4 aut
2451 0a The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers
264 1b Elsevier BV,c 2015
520 a Objective: To evaluate the additive value of the prostate cancer gene 3 (PCA3) urine test to serum prostate-specific antigen (PSA) in prostate cancer (PC) screening among breast cancer, early-onset gene (BRCA) mutation carriers. This study was performed among the Dutch participants of IMPACT, a large international study on the effectiveness of PSA screening among BRCA mutation carriers. Materials and methods: Urinary PCA3 was measured in 191 BRCA1 mutation carriers, 75 BRCA2 mutation carriers, and 308 noncarriers. The physicians and participants were blinded for the results. Serum PSA level≥3.0. ng/ml was used to indicate prostate biopsies. PCA3 was evaluated (1) as an independent indicator for prostate biopsies and (2) as an indicator for prostate biopsies among men with an elevated PSA level. PC detected up to the 2-year screening was used as gold standard as end-of-study biopsies were not performed. Results: Overall, 23 PCs were diagnosed, 20 of which were in men who had an elevated PSA level in the initial screening round. (1) PCA3, successfully determined in 552 participants, was elevated in 188 (cutoff≥25; 34%) or 134 (cutoff≥35; 24%) participants, including 2 of the 3 PCs missed by PSA. PCA3 would have added 157 (≥25; 28%) or 109 (≥35; 20%) biopsy sessions to screening with PSA only. (2) Elevated PCA3 as a requirement for biopsies in addition to PSA would have saved 37 (cutoff≥25) or 43 (cutoff≥35) of the 68 biopsy sessions, and 7 or 11 PCs would have been missed, respectively, including multiple high-risk PCs. So far, PCA3 performed best among BRCA2 mutation carriers, but the numbers are still small. Because PCA3 was not used to indicate prostate biopsies, its true diagnostic value cannot be calculated. Conclusions: The results do not provide evidence for PCA3 as a useful additional indicator of prostate biopsies in BRCA mutation carriers, as many participants had an elevated PCA3 in the absence of PC. This must be interpreted with caution because PCA3 was not used to indicate biopsies. Many participants diagnosed with PC had low PCA3, making it invalid as a restrictive marker for prostate biopsies in men with elevated PSA levels.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Medicinsk genetik0 (SwePub)301072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Medical Genetics0 (SwePub)301072 hsv//eng
653 a BRCA2
653 a Diagnostic value
653 a Marker
653 a PCA3
653 a Prostate cancer gene 3
653 a PSA
7001 a Eeles, Rosalind A.u Institute of Cancer Research London,Royal Marsden NHS Foundation Trust4 aut
7001 a Bancroft, E. K.u Institute of Cancer Research London,Royal Marsden NHS Foundation Trust4 aut
7001 a Ringelberg-Borsboom, Jannekeu The Netherlands Foundation for the Detection of Hereditary Tumours4 aut
7001 a Vasen, Hans F.u The Netherlands Foundation for the Detection of Hereditary Tumours4 aut
7001 a Van Asperen, Christi J.u Leiden University Medical Centre4 aut
7001 a Schalken, Jack A.u Radboud University Medical Center4 aut
7001 a Verhaegh, Gerald W.u Radboud University Medical Center4 aut
7001 a Kiemeney, Lambertus A.u Radboud University Medical Center4 aut
7001 a Aaronson, N.u Netherlands Cancer Institute4 aut
7001 a Ardem-Jones, A.u Royal Marsden NHS Foundation Trust4 aut
7001 a Bancroft, E. K.u Royal Marsden NHS Foundation Trust,Institute of Cancer Research London4 aut
7001 a Bangma, C.u Erasmus University Medical Center4 aut
7001 a Castro, E.u Institute of Cancer Research London,Spanish National Cancer Research Center (CNIO)4 aut
7001 a Dearnaley, D.u Institute of Cancer Research London4 aut
7001 a Eccles, D.u Princess Anne Hospital4 aut
7001 a Eeles, R. A.u Royal Marsden NHS Foundation Trust,Netherlands Cancer Institute4 aut
7001 a Evans, D. G.u Manchester University NHS Foundation Trust4 aut
7001 a Eyfjord, J.u University of Iceland4 aut
7001 a Falconer, A.u Imperial College Healthcare NHS Trust4 aut
7001 a Foster, C. S.u HCA Healthcare Laboratories4 aut
7001 a Grönberg, H.u Norrland University Hospital4 aut
7001 a Hamdy, F. C.u Churchill Hospital,University of Oxford4 aut
7001 a Johansson, O.u National University Hospital of Iceland4 aut
7001 a Khoo, V.u Royal Marsden NHS Foundation Trust4 aut
7001 a Kote-Jarai, Z.u Institute of Cancer Research London4 aut
7001 a Lilja, H.u Lund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups,University of Tampere,University of Oxford,Memorial Sloan-Kettering Cancer Center4 aut0 (Swepub:lu)klke-hli
7001 a Lubinski, J.u Pomeranian Medical University4 aut
7001 a Maehle, L.u Norwegian Radium Hospital4 aut
7001 a Melia, J.u University of Cambridge4 aut
7001 a Mikropoulos, C.u Institute of Cancer Research London4 aut
7001 a Mitchell, G.u University of Melbourne,Peter MacCallum Cancer Centre4 aut
7001 a Mitra, A. V.u Institute of Cancer Research London,Royal Free Hospital4 aut
7001 a Moss, S.u Queen Mary University4 aut
7001 a Moynihan, C.u Institute of Cancer Research London4 aut
7001 a Page, E. C.u Institute of Cancer Research London4 aut
7001 a Rennert, G.u Carmel Medical Center4 aut
7001 a Suri, M.u Nottingham City Hospital4 aut
7001 a Wilson, P.u BioZenix4 aut
7102 a Radboud University Medical Centerb Institute of Cancer Research London4 org
7102 a The IMPACT Steering Committee
7730 t Urologic Oncology: Seminars and Original Investigationsd : Elsevier BVg 33:5, s. 19-202q 33:5<19-202x 1078-1439
8564 u http://dx.doi.org/10.1016/j.urolonc.2015.01.018x freey FULLTEXT
8564 u https://doi.org/10.1016/j.urolonc.2015.01.018
8564 8u https://lup.lub.lu.se/record/79aa491e-8aa0-4f69-b2d8-f9427ef30dfa
8564 8u https://doi.org/10.1016/j.urolonc.2015.01.018

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy